Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2026 Jan:204:79-90.
doi: 10.1016/j.ygyno.2025.10.030. Epub 2025 Nov 24.

Radiation therapy for the gynecologic oncologist

Affiliations
Review

Radiation therapy for the gynecologic oncologist

Han T Cun et al. Gynecol Oncol. 2026 Jan.

Abstract

Radiation therapy for the gynecologic oncology patient has evolved in the last century but continues to be an integral component of care for women with pelvic malignancies. This review discusses the essential aspects of physics, radiobiology, and imaging for radiation therapy. It aims to review the increasing indications for radiation therapy in gynecologic neoplasms such as for oligometastatic disease and palliative measures. It also discusses the widespread adoption of IMRT, increasing use of SBRT and proton beam therapy, and modernization of brachytherapy in gynecological cancer, while also touching on the interdigitation of immunotherapy, as well as the impact of molecular factors in adjuvant endometrial cancer treatment. Radiation oncology, like other oncologic disciplines, continues to evolve to provide less morbidity with improved outcomes and experience for our patients. And thus, the following review discusses innovations in radiotherapy used in gynecologic malignancies today and the advances we see impacting the field of gynecologic oncology moving forward.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. David Gaffney is the NRG Oncology Gynecology co-chair, Board Member of IGCS, Associate Editor of Gynecologic Oncology, DSMC chair for Merck cervix study, and has Clinical Trial funding from Elekta on Vaginal brachytherapy. But all other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. During the preparation of this work, the authors did not use any generative AI or AI-assisted technologies in the writing process.

LinkOut - more resources